The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; Petra Pharma; PIC Therapeutics; Relay Therapeutics; Silverback Therapeutics; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Eisai (Inst); EMD Serono (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Placon (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis
Consulting or Advisory Role - Napo Pharmaceuticals
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)
 
Albert Reising
Employment - Novartis; Novartis
Stock and Other Ownership Interests - Novartis
 
Chong Ma
Employment - Novartis; Takeda (I)
 
Eva M. Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Medscape (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Samsung (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
 
Christian F. Singer
Honoraria - AstraZeneca/MedImmune; Daiichi Sankyo Europe GmbH; Novartis
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi-Sanyko; Gilead Sciences; Novartis; Sanofi/Aventis
Speakers' Bureau - AstraZeneca/MedImmune; Novartis
Research Funding - AstraZeneca/MedImmune; Myriad Genetics; Novartis; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Roche
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - Roche
 
Mario Campone
Honoraria - GT1; Lilly; Novartis
Consulting or Advisory Role - Abbvie (Inst); Accord Healthcare (Inst); AstraZeneca/MedImmune (Inst); Daiichi Sankyo Europe GmbH; Lilly (Inst); Menarini; Novartis (Inst); Pfizer; Pierre Fabre (Inst); Sandoz-Novartis (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst)
Speakers' Bureau - Amgen; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
Other Relationship - Roche
 
Pierfranco Conte
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Gilead Sciences; Reveal Genomics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Roche/Genentech; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2Dx Patent
Expert Testimony - AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Pfizer
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Farhat Ghaznawi
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Michelle Kristine Miller
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Tetiana Taran
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Fei Su
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Fabrice Andre
Stock and Other Ownership Interests - PEGASCY
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche